Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1995 Nov 1;182(5):1517–1525. doi: 10.1084/jem.182.5.1517

Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48- kD DNA-binding protein, ISGF3-gamma

PMCID: PMC2192209  PMID: 7595221

Abstract

Interferon (IFN) gamma, a cardinal proinflammatory cytokine, induces expression of the gene products of the class II locus of the major histocompatibility complex (MHC), whereas IFN-alpha or -beta suppresses MHC class II expression. The mechanism of IFN-beta-mediated MHC class II inhibition has been unclear. Recently, a novel factor termed class II transactivator (CIITA) has been identified as essential for IFN- gamma-induced MHC class II transcription. We studied the status of IFN- gamma-induced CIITA messenger RNA (mRNA) accumulation and CIITA-driven transactivation in IFN-beta-treated cells and used cell lines that had defined defects in the type I IFN response pathway to address the roles of IFN signaling components in the inhibition of MHC class II induction. IFN-beta treatment did not suppress IFN-gamma-induced accumulation of CIITA mRNA. After cells were stably transfected with CIITA, endogenous MHC class II genes were constitutively expressed, and MHC class II promoters, delivered by transfection, were actively transcribed in CIITA-expressing cells. Expression of these promoters was significantly impaired by pretreatment with IFN-beta. These results suggest that IFN-beta acts downstream of CIITA mRNA accumulation, and acts in part by reducing the functional competence of CIITA for transactivating MHC class II promoters. IFN stimulated gene factor 3 (ISGF3) gamma was essential for IFN-beta to mediate inhibition of MHC class II induction, regardless of whether MHC class II transcription was stimulated by IFN-gamma or directly by CIITA expression. Results of these experiments suggest that inhibition of MHC class II in IFN-beta- treated cells requires expression of gene(s) directed by the ISGF3-IFN- stimulated response element pathway, and that these gene product(s) may act by blocking CIITA-driven transcription of MHC class II promoters.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amaldi I., Reith W., Berte C., Mach B. Induction of HLA class II genes by IFN-gamma is transcriptional and requires a trans-acting protein. J Immunol. 1989 Feb 1;142(3):999–1004. [PubMed] [Google Scholar]
  2. Barna B. P., Chou S. M., Jacobs B., Yen-Lieberman B., Ransohoff R. M. Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol. 1989 Jun;23(1):45–53. doi: 10.1016/0165-5728(89)90072-6. [DOI] [PubMed] [Google Scholar]
  3. Blanar M. A., Boettger E. C., Flavell R. A. Transcriptional activation of HLA-DR alpha by interferon gamma requires a trans-acting protein. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4672–4676. doi: 10.1073/pnas.85.13.4672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chang C. H., Fontes J. D., Peterlin M., Flavell R. A. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med. 1994 Oct 1;180(4):1367–1374. doi: 10.1084/jem.180.4.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chin K. C., Mao C., Skinner C., Riley J. L., Wright K. L., Moreno C. S., Stark G. R., Boss J. M., Ting J. P. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity. 1994 Nov;1(8):687–697. doi: 10.1016/1074-7613(94)90039-6. [DOI] [PubMed] [Google Scholar]
  6. Cogswell J. P., Zeleznik-Le N., Ting J. P. Transcriptional regulation of the HLA-DRA gene. Crit Rev Immunol. 1991;11(2):87–112. [PubMed] [Google Scholar]
  7. Darnell J. E., Jr, Kerr I. M., Stark G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994 Jun 3;264(5164):1415–1421. doi: 10.1126/science.8197455. [DOI] [PubMed] [Google Scholar]
  8. Devajyothi C., Kalvakolanu I., Babcock G. T., Vasavada H. A., Howe P. H., Ransohoff R. M. Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells. Definition of cis-element. J Biol Chem. 1993 Sep 5;268(25):18794–18800. [PubMed] [Google Scholar]
  9. Fertsch-Ruggio D., Schoenberg D. R., Vogel S. N. Induction of macrophage Ia antigen expression by rIFN-gamma and down-regulation by IFN-alpha/beta and dexamethasone are regulated transcriptionally. J Immunol. 1988 Sep 1;141(5):1582–1589. [PubMed] [Google Scholar]
  10. Friedman R. L., Manly S. P., McMahon M., Kerr I. M., Stark G. R. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell. 1984 Oct;38(3):745–755. doi: 10.1016/0092-8674(84)90270-8. [DOI] [PubMed] [Google Scholar]
  11. Haque S. J., Williams B. R. Identification and characterization of an interferon (IFN)-stimulated response element-IFN-stimulated gene factor 3-independent signaling pathway for IFN-alpha. J Biol Chem. 1994 Jul 29;269(30):19523–19529. [PubMed] [Google Scholar]
  12. Inaba K., Kitaura M., Kato T., Watanabe Y., Kawade Y., Muramatsu S. Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigens. J Exp Med. 1986 Apr 1;163(4):1030–1035. doi: 10.1084/jem.163.4.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. John J., McKendry R., Pellegrini S., Flavell D., Kerr I. M., Stark G. R. Isolation and characterization of a new mutant human cell line unresponsive to alpha and beta interferons. Mol Cell Biol. 1991 Aug;11(8):4189–4195. doi: 10.1128/mcb.11.8.4189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kara C. J., Glimcher L. H. Regulation of MHC class II gene transcription. Curr Opin Immunol. 1991 Feb;3(1):16–21. doi: 10.1016/0952-7915(91)90070-h. [DOI] [PubMed] [Google Scholar]
  15. Krief P., Augery-Bourget Y., Plaisance S., Merck M. F., Assier E., Tanchou V., Billard M., Boucheix C., Jasmin C., Azzarone B. A new cytokine (IK) down-regulating HLA class II: monoclonal antibodies, cloning and chromosome localization. Oncogene. 1994 Dec;9(12):3449–3456. [PubMed] [Google Scholar]
  16. Levy D. E., Lew D. J., Decker T., Kessler D. S., Darnell J. E., Jr Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J. 1990 Apr;9(4):1105–1111. doi: 10.1002/j.1460-2075.1990.tb08216.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ling P. D., Warren M. K., Vogel S. N. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol. 1985 Sep;135(3):1857–1863. [PubMed] [Google Scholar]
  18. Loh J. E., Chang C. H., Fodor W. L., Flavell R. A. Dissection of the interferon gamma-MHC class II signal transduction pathway reveals that type I and type II interferon systems share common signalling component(s). EMBO J. 1992 Apr;11(4):1351–1363. doi: 10.1002/j.1460-2075.1992.tb05180.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mach B., Gorski J., Rollini P., Berte C., Amaldi I., Berdoz J., Ucla C. Polymorphism and regulation of HLA class II genes of the major histocompatibility complex. Cold Spring Harb Symp Quant Biol. 1986;51(Pt 1):67–74. doi: 10.1101/sqb.1986.051.01.009. [DOI] [PubMed] [Google Scholar]
  20. Mach B. MHC class II regulation--lessons from a disease. N Engl J Med. 1995 Jan 12;332(2):120–122. doi: 10.1056/NEJM199501123320211. [DOI] [PubMed] [Google Scholar]
  21. Mao C., Davies D., Kerr I. M., Stark G. R. Mutant human cells defective in induction of major histocompatibility complex class II genes by interferon gamma. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2880–2884. doi: 10.1073/pnas.90.7.2880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McKendry R., John J., Flavell D., Müller M., Kerr I. M., Stark G. R. High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11455–11459. doi: 10.1073/pnas.88.24.11455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Müller M., Briscoe J., Laxton C., Guschin D., Ziemiecki A., Silvennoinen O., Harpur A. G., Barbieri G., Witthuhn B. A., Schindler C. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature. 1993 Nov 11;366(6451):129–135. doi: 10.1038/366129a0. [DOI] [PubMed] [Google Scholar]
  24. Müller M., Laxton C., Briscoe J., Schindler C., Improta T., Darnell J. E., Jr, Stark G. R., Kerr I. M. Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. EMBO J. 1993 Nov;12(11):4221–4228. doi: 10.1002/j.1460-2075.1993.tb06106.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Oliveira I. C., Sciavolino P. J., Lee T. H., Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9049–9053. doi: 10.1073/pnas.89.19.9049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Panitch H. S., Hirsch R. L., Haley A. S., Johnson K. P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987 Apr 18;1(8538):893–895. doi: 10.1016/s0140-6736(87)92863-7. [DOI] [PubMed] [Google Scholar]
  27. Panitch H. S., Hirsch R. L., Schindler J., Johnson K. P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987 Jul;37(7):1097–1102. doi: 10.1212/wnl.37.7.1097. [DOI] [PubMed] [Google Scholar]
  28. Pellegrini S., John J., Shearer M., Kerr I. M., Stark G. R. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol Cell Biol. 1989 Nov;9(11):4605–4612. doi: 10.1128/mcb.9.11.4605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Politis A. D., Ozato K., Coligan J. E., Vogel S. N. Regulation of IFN-gamma-induced nuclear expression of IFN consensus sequence binding protein in murine peritoneal macrophages. J Immunol. 1994 Mar 1;152(5):2270–2278. [PubMed] [Google Scholar]
  30. Ransohoff R. M., Devajyothi C., Estes M. L., Babcock G., Rudick R. A., Frohman E. M., Barna B. P. Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J Neuroimmunol. 1991 Aug;33(2):103–112. doi: 10.1016/0165-5728(91)90054-b. [DOI] [PubMed] [Google Scholar]
  31. Ransohoff R. M., Tuohy V. K., Barna B. P., Rudick R. A. Monocytes in active multiple sclerosis: intact regulation of HLA-DR density in vitro despite decreased HLA-DR density in vivo. J Neuroimmunol. 1992 Apr;37(3):169–176. doi: 10.1016/0165-5728(92)90001-2. [DOI] [PubMed] [Google Scholar]
  32. Riley J. L., Westerheide S. D., Price J. A., Brown J. A., Boss J. M. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). Immunity. 1995 May;2(5):533–543. doi: 10.1016/1074-7613(95)90033-0. [DOI] [PubMed] [Google Scholar]
  33. Silacci P., Mottet A., Steimle V., Reith W., Mach B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med. 1994 Oct 1;180(4):1329–1336. doi: 10.1084/jem.180.4.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Song Z., Krishna S., Thanos D., Strominger J. L., Ono S. J. A novel cysteine-rich sequence-specific DNA-binding protein interacts with the conserved X-box motif of the human major histocompatibility complex class II genes via a repeated Cys-His domain and functions as a transcriptional repressor. J Exp Med. 1994 Nov 1;180(5):1763–1774. doi: 10.1084/jem.180.5.1763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Southern P. J., Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet. 1982;1(4):327–341. [PubMed] [Google Scholar]
  36. Stark G. R., Kerr I. M. Interferon-dependent signaling pathways: DNA elements, transcription factors, mutations, and effects of viral proteins. J Interferon Res. 1992 Jun;12(3):147–151. doi: 10.1089/jir.1992.12.147. [DOI] [PubMed] [Google Scholar]
  37. Steimle V., Otten L. A., Zufferey M., Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 1993 Oct 8;75(1):135–146. [PubMed] [Google Scholar]
  38. Steimle V., Siegrist C. A., Mottet A., Lisowska-Grospierre B., Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994 Jul 1;265(5168):106–109. doi: 10.1126/science.8016643. [DOI] [PubMed] [Google Scholar]
  39. Ting J. P., Baldwin A. S. Regulation of MHC gene expression. Curr Opin Immunol. 1993 Feb;5(1):8–16. doi: 10.1016/0952-7915(93)90074-3. [DOI] [PubMed] [Google Scholar]
  40. Ting J. P., Painter A., Zeleznik-Le N. J., MacDonald G., Moore T. M., Brown A., Schwartz B. D. YB-1 DNA-binding protein represses interferon gamma activation of class II major histocompatibility complex genes. J Exp Med. 1994 May 1;179(5):1605–1611. doi: 10.1084/jem.179.5.1605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Velazquez L., Fellous M., Stark G. R., Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 1992 Jul 24;70(2):313–322. doi: 10.1016/0092-8674(92)90105-l. [DOI] [PubMed] [Google Scholar]
  42. Watling D., Guschin D., Müller M., Silvennoinen O., Witthuhn B. A., Quelle F. W., Rogers N. C., Schindler C., Stark G. R., Ihle J. N. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature. 1993 Nov 11;366(6451):166–170. doi: 10.1038/366166a0. [DOI] [PubMed] [Google Scholar]
  43. Weinstock-Guttman B., Ransohoff R. M., Kinkel R. P., Rudick R. A. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol. 1995 Jan;37(1):7–15. doi: 10.1002/ana.410370105. [DOI] [PubMed] [Google Scholar]
  44. Zhou H., Glimcher L. H. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity. 1995 May;2(5):545–553. doi: 10.1016/1074-7613(95)90034-9. [DOI] [PubMed] [Google Scholar]
  45. de Préval C., Lisowska-Grospierre B., Loche M., Griscelli C., Mach B. A trans-acting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes. Nature. 1985 Nov 21;318(6043):291–293. doi: 10.1038/318291a0. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES